Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, Netherlands.
J Clin Pharm Ther. 2013 Oct;38(5):379-87. doi: 10.1111/jcpt.12069. Epub 2013 Apr 26.
Limited and conflicting evidence exists on the effect of a multicomponent pharmaceutical care intervention (i.e. medication review, involving collaboration between general practitioners (GPs), pharmacists and patients) on medication-related hospitalizations, survival, adverse drug events (ADEs) and quality of life. We aimed to investigate the effect of a multicomponent pharmaceutical care intervention on these outcomes.
An open controlled multicentre study was conducted within primary care settings. Patients with a high risk on medication-related hospitalizations based on old age, use of five or more medicines, non-adherence and type of medication used were included. The intervention consisted of a patient interview, a review of the pharmacotherapy and the execution and follow-up evaluation of a pharmaceutical care plan. The patient's own pharmacist and GP carried out the intervention. The control group received usual care and was cared for by a GP other than the intervention GP. The primary outcome of the study was the frequency of hospital admissions related to medication within the study period of 12 months for each patient. Secondary outcomes were survival, quality of life and ADEs.
364 intervention and 310 control patients were included. Less medication-related hospital admissions were found in the intervention group (n = 6; 1·6%) than in the control group (n = 10; 3·2%) but the overall effect was not statistically significant (hazard ratio (HR) 0·50, 95% confidence interval (CI) 0·12-1·59). The secondary outcomes were not statistically significantly different either. The study was underpowered, which may explain the negative results. A post hoc analysis showed that the effect of the intervention was statistically significant for patients with five diseases or more: five diseases, HR 0·28 (95% bootstrap CI: 0·056-0·73) and eight diseases, HR 0·11 (95% CI: 0·013-0·34).
A multicomponent pharmaceutical care intervention does not prevent medication-related hospital admissions. Whether this is true for such interventions in general is unknown, because the PHARM study was underpowered. The intervention may significantly reduce medication-related hospitalizations in patients with five or more comorbidities, but this is only based on a post hoc analysis and thus needs confirmation in large controlled trials.
关于多组分药物治疗干预(即药物审查,涉及全科医生 [GP]、药剂师和患者之间的合作)对与药物相关的住院、生存、药物不良事件(ADE)和生活质量的影响,证据有限且相互矛盾。我们旨在研究多组分药物治疗干预对这些结果的影响。
在初级保健环境中进行了一项开放的对照性多中心研究。纳入了因年龄较大、使用五种或更多药物、不依从和使用药物类型而处于与药物相关的住院高风险的患者。干预措施包括患者访谈、药物治疗审查以及执行和随访评估药物治疗计划。患者自己的药剂师和 GP 进行干预。对照组接受常规护理,并由干预 GP 以外的 GP 提供护理。该研究的主要结果是每位患者在 12 个月的研究期间因药物相关住院的住院频率。次要结果是生存、生活质量和 ADE。
纳入了 364 名干预组和 310 名对照组患者。干预组(n = 6;1.6%)发生与药物相关的住院治疗次数少于对照组(n = 10;3.2%),但总体效果无统计学意义(风险比 [HR] 0.50,95%置信区间 [CI] 0.12-1.59)。次要结果也无统计学差异。该研究的效能不足,这可能解释了阴性结果。事后分析显示,该干预对患有五种或更多疾病的患者的效果具有统计学意义:五种疾病,HR 0.28(95% bootstrap CI:0.056-0.73)和八种疾病,HR 0.11(95% CI:0.013-0.34)。
多组分药物治疗干预不能预防与药物相关的住院治疗。这种干预措施是否普遍如此,目前尚不清楚,因为 PHARM 研究的效能不足。该干预措施可能会显著减少患有五种或更多合并症的患者的与药物相关的住院治疗,但这仅基于事后分析,因此需要在大型对照试验中进行验证。